Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morning versus evening Rebif 44 µg three-times-weekly administration in relapsing multiple sclerosis
2013-004450-21Phase 4Completed
- Sponsor
- Merck Serono
- Start
- Dec 2013
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of interferon beta-1a in multiple sclerosis (MS) (2 arms), sponsored by Merck Serono. Primary endpoint: Difference in flu-like symptoms score at week 12. Started Dec 2013; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2013-004450-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004450-21.